Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma. - Motzer,R.J.; Amato,R.; Todd,M.; Hwu,W.J.; Cohen,R.; Baselga,J.; Muss,H.; Cooper,M.; Yu,R.; Ginsberg,M.S.; Needle,M. (Invest New Drugs, 2003)